Science News
from research organizations

Cancer drugs approved quickly but not to patient's benefit, researcher says

Date:
May 7, 2015
Source:
York University
Summary:
Highly priced cancer drugs get rushed approvals despite poor trial methodology and little effect on the longevity of patients, cautions one expert, who adds that drug reviewers don't look at the long term survival of patients who take them.
Share:
FULL STORY

Highly priced cancer drugs get rushed approvals despite poor trial methodology and little effect on the longevity of patients, cautions York University Professor Dr. Joel Lexchin in the School of Health Policy and Management.

"Patients and their doctors should demand that regulators require pharma companies to provide clear evidence of clinical effectiveness of the drugs, resulting from rigorous methodology," suggests Lexchin. "Drug agencies like the Food and Drug Administration (FDA) and the European Medicine Agency (EMA) don't actually look at whether people live longer."

In an article in the British Medical Journal, titled "Why do cancer drugs get such an easy ride?," Lexchiin and co-author Donald Light, a professor in the School of Osteopathic Medicine, Rowan University in New Jersey, note that accelerated approval and shortened review times also make it a smooth sail for cancer drugs.

Lexchin cites earlier research reviewing solid cancer drugs within 10 years of EMA approval to point out that these drugs improved survival by just over a month.

"Similarly 71 drugs approved by the FDA from 2002 to 2014 for solid tumours have resulted in median gains in progression-free and overall survival of only 2.5 and 2.1 months, respectively," he says adding, "Also, only 42 per cent met the American Society of Clinical Oncology Cancer Research Committee's criteria for meaningful results for patients."


Story Source:

Materials provided by York University. Note: Content may be edited for style and length.


Journal Reference:

  1. D. W. Light, J. Lexchin. Why do cancer drugs get such an easy ride? BMJ, 2015; 350 (apr23 1): h2068 DOI: 10.1136/bmj.h2068

Cite This Page:

York University. "Cancer drugs approved quickly but not to patient's benefit, researcher says." ScienceDaily. ScienceDaily, 7 May 2015. <www.sciencedaily.com/releases/2015/05/150507135917.htm>.
York University. (2015, May 7). Cancer drugs approved quickly but not to patient's benefit, researcher says. ScienceDaily. Retrieved May 23, 2017 from www.sciencedaily.com/releases/2015/05/150507135917.htm
York University. "Cancer drugs approved quickly but not to patient's benefit, researcher says." ScienceDaily. www.sciencedaily.com/releases/2015/05/150507135917.htm (accessed May 23, 2017).

RELATED STORIES